trazodone has been researched along with Lewy Body Disease in 1 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
Lewy Body Disease: A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trazodone is a serotonin reuptake inhibitor and a 5-HT2 receptor antagonist: it is effective in the treatment of the frontal syndrome and is commonly used in frontotemporal degeneration." | 5.91 | [Pimavanserin and trazodone combination in behavioral disorders in severe dementia with Lewy bodies]. ( Blanc, F; Javelot, H; Merignac, J; Moog, C; Muller, C; Schorr, B, 2023) |
| "Trazodone is a serotonin reuptake inhibitor and a 5-HT2 receptor antagonist: it is effective in the treatment of the frontal syndrome and is commonly used in frontotemporal degeneration." | 1.91 | [Pimavanserin and trazodone combination in behavioral disorders in severe dementia with Lewy bodies]. ( Blanc, F; Javelot, H; Merignac, J; Moog, C; Muller, C; Schorr, B, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muller, C | 1 |
| Merignac, J | 1 |
| Moog, C | 1 |
| Schorr, B | 1 |
| Javelot, H | 1 |
| Blanc, F | 1 |
1 other study available for trazodone and Lewy Body Disease
| Article | Year |
|---|---|
[Pimavanserin and trazodone combination in behavioral disorders in severe dementia with Lewy bodies].
Topics: Clozapine; Dementia; Drug Inverse Agonism; Hallucinations; Humans; Lewy Body Disease; Trazodone | 2023 |